OBJECTIVE	To evaluate the efficacy and safety of oral treatment with the antioxidant alpha-lipoic acid ( ALA ) in NIDDM patients with cardiac autonomic neuropathy ( CAN ) , assessed by heart rate variability ( HRV ) .\